



## **iJOBS Virtual Site Visit: GSK**

Tuesday, July 7, 2020

1:00 - 2:30 pm



**Aaron T. Cheng, PhD**

**Functional Genomics**

**GlaxoSmithKline**

[aaron.t.cheng@gsk.com](mailto:aaron.t.cheng@gsk.com)

1-510-725-7721

Aaron Cheng joined GSK in 2014 and is currently a team leader within the Gene Editing and Genetic Screening group of Functional Genomics. Aaron is based out of the US Research Hub in Upper Providence, PA and his team deploys pooled and arrayed screening strategies for target discovery across a number of therapeutic areas including synthetic lethality and immuno-oncology.

Since joining GSK, Aaron has assumed roles of diverse and increasing responsibility including as Investigator in the Biological Sciences department, Biology Lead in Drug Delivery and, most recently, as Head of the Platform Technology and Science Discovery Genome Editing, where he led strategy and deployment of innovative applications of gene editing across drug discovery and development. Aaron began his scientific career in waders, studying jellyfish ecology off the coast of Seattle at the University of Washington's Friday Harbor Laboratories. He then studied under Kanta Subbarao as a Fellow in the Laboratory of Infectious Diseases at the National Institutes of Health, where he contributed to the development of animal models for the study of SARS coronavirus pathogenesis in response to the 2004 Asia outbreak. As a graduate student at UC Berkeley, in the *B.C. (before CRISPR)* days, Aaron pioneered use of zinc-finger nucleases for endogenous multi-gene tagging and its application for the study of protein dynamics; specifically, he applied these methods in somatic and human ES/iPSCs to uncover mechanistic understanding of dynamic, cytoskeletal-driven cellular processes. His doctoral studies culminated with establishment of CRISPR/Cas9 editing in eukaryotic cell systems in collaboration with the laboratory of Jennifer Doudna.

Aaron received his BA in Biology from Swarthmore College and his PhD in Molecular and Cell Biology from the University of California, Berkeley.



**Haydee Lara, PhD**

**Biomarker Analyst Scientist**

**GlaxoSmithKline**

[haydee.p.lara@gsk.com](mailto:haydee.p.lara@gsk.com)

My role includes:

Using Artificial Intelligence & traditional microscopy to study clinical samples (e.g. biopsies)

Developing staining assays (immunohistochemistry) to detect cancer and normal cells (e.g. tumor, inflammation) in biopsies

Before this job, I was: A Postdoctoral Researcher doing Cell & Molecular Biology at GSK and UNC-Chapel Hill (Go Heels!!!)

Outside of this job: I like traveling, paintball, hiking, museums and other fun stuff

A typical day for me may include: Looking at the microscope (aka my computer screen)

Using the 'robots'



**Michal Magid-Slav, PhD**  
**Computational Biologist**  
**GlaxoSmithKline**

[michal.m.magid-slav@gsk.com](mailto:michal.m.magid-slav@gsk.com)

Michal Magid-Slav is a Scientific Director and Computational Biology Team Leader in Functional Genomics, MST in Upper Providence. Michal received her M.Sc. in Biology from The Weizmann Institute of Science, Israel, finished her graduate studies in Bioinformatics from University of Pennsylvania in 2001, and received her MBA from Drexel University in 2012. Michal joined GlaxoSmithKline in 2001 and has 19 years of experience in drug discovery on a wide variety of therapeutic areas at various stages of the drug discovery and development pipeline. In addition, Michal is a certified Job Plus Coach and a Champion for Inclusion and Diversity.



**Greg Tabor, PhD**  
**Chemical Biologist**  
**GlaxoSmithKline**

[greg.x.tabor@gsk.com](mailto:greg.x.tabor@gsk.com)

**Greg Tabor** joined GSK in 2017 as a medicinal chemist in the Immuno-Oncology DPU. Prior to joining GSK, he completed his doctoral and postdoctoral training at Scripps Research. He spent his time between a variety of projects and received awards for his contributions to the IOC portfolio. Afterwards, Greg transitioned to Chemical Biology where he now leads efforts to accelerate the generation of tractability assessments for targets in the small molecule portfolio. Along with his work in Chemical Biology, Greg is also involved in a variety of activities at GSK. Greg serves as the Inclusion & Diversity Lead for Medicine Design and is part of the GSK-Northeastern University Collaborative Ph.D. Program as an industrial advisor where he supervises Ph.D. students. Outside of work Greg is an avid photographer and enjoys travelling to scenic locations with his wife and daughter.

**Lamont R. Terrell, PhD**  
**Inclusion and Diversity Lead, Pharma R&D**

[Lamont.R.Terrell@gsk.com](mailto:Lamont.R.Terrell@gsk.com)

1-610-917-4979